Evaluation of SARS-Co-V-2 Vaccine in Younger and Older Adults

The coronavirus pandemic has continued to spread throughout the world with 109 million confirmed cases and 2.4 million deaths as recorded in Feb 2021. There is a growing need for safe vaccines to prevent COVID19 throughout the world. The NVX-CoV2373 vaccine contains Matrix M1 adjuvant and Recombinant SARS-Co-V-2 nanoparticle constructed from full-length wild type SARS-Co-V-2 spike glycoprotein, which serves as the target for the development of antibodies. Targeting SARS-Co-V-2 spike glycoprotein is highly effective as per the research of COVID19 vaccines.

A study was conducted which suggested that the NVX-CoV2373 vaccine was highly immunogenic and well-tolerated based on a phase 1 trial. The 2 dose regime of 5 micrograms of NVX-CoV2373 vaccine, administered 21 days apart, was considered the optimal dose. There were two immunogenicity outcomes which were as follows: the anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses. Following 1 st vaccination, NVX-CoV2373 vaccine dose levels were well tolerated with no difference in the anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses were noted. Following the 2nd vaccination, both doses of NVX-CoV2373 vaccine remain well tolerated however NVX-CoV2373 vaccine induced robust levels of anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses in both younger and older adults.

There was a high correlation between anti-spike protein building IgG and Neutralizing Antibodies (NAb) suggesting anti-spike immunity indicating neutralization. Based on antibody responses, the low dose, and two immunization regime of 5 micrograms of NVX-CoV2373 vaccine was selected to move into later phase development.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link: https://doi.org/10.1101/2021.02.26.2125248

#Featured